Literature DB >> 19933900

Generalizing the results of cancer clinical trials.

Ralph M Meyer.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19933900     DOI： 10.1200/JCO.2009.25.8608

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  Uptake of novel medical therapies in the general population.

Authors:  C M Booth; B Rapoport
Journal:  Curr Oncol       Date:  2011-06       Impact factor: 3.677

2.  Achieving the achievable in muscle-invasive bladder cancer.

Authors:  Christopher M Booth; William J Mackillop
Journal:  Can Urol Assoc J       Date:  2012-08       Impact factor: 1.862

Review 3.  Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.

Authors:  Ralph M Meyer; Richard T Hoppe
Journal:  Blood       Date:  2012-07-20       Impact factor: 22.113

4.  Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres.

Authors:  Y Madarnas; S F Dent; S F Husain; A Robinson; S Alkhayyat; W M Hopman; J L Verreault; T Vandenberg
Journal:  Curr Oncol       Date:  2011-06       Impact factor: 3.677

5.  External Validation of Two Established Clinical Risk Scores Predicting Outcome after Local Treatment of Colorectal Liver Metastases in a Nationwide Cohort.

Authors:  Karen Bolhuis; G Emerens Wensink; Marloes A G Elferink; Marinde J G Bond; Willemieke P M Dijksterhuis; Remond J A Fijneman; Onno W Kranenburg; Inne H M Borel Rinkes; Miriam Koopman; Rutger-Jan Swijnenburg; Geraldine R Vink; Jeroen Hagendoorn; Cornelis J A Punt; Sjoerd G Elias; Jeanine M L Roodhart
Journal:  Cancers (Basel)       Date:  2022-05-10       Impact factor: 6.575

6.  Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes.

Authors:  Inna Y Gong; Andrew T Yan; Craig C Earle; Maureen E Trudeau; Andrea Eisen; Kelvin K W Chan
Journal:  Breast Cancer Res Treat       Date:  2020-03-31       Impact factor: 4.872

7.  Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma.

Authors:  Xiaoyu Zhai; Qiwen Zheng; Lu Yang; Yixiang Zhu; Junling Li; Yutao Liu; Ziping Wang
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

Review 8.  Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data.

Authors:  Jee Ae Kim; Seokjun Yoon; Log Young Kim; Dong Sook Kim
Journal:  J Korean Med Sci       Date:  2017-05       Impact factor: 2.153

9.  Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence.

Authors:  C M Booth; I F Tannock
Journal:  Br J Cancer       Date:  2014-01-14       Impact factor: 7.640

10.  Is there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer?

Authors:  Yutao Liu; Xiaoyu Zhai; Junling Li; Zhiwen Li; Di Ma; Ziping Wang
Journal:  Chin J Cancer Res       Date:  2017-06       Impact factor: 5.087
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.